Cara Therapeutics Inc (CARA)
0.7697
+0.03
(+4.22%)
USD |
NASDAQ |
May 02, 12:44
Cara Therapeutics Free Cash Flow: -94.45M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -94.45M |
| September 30, 2023 | -98.54M |
| June 30, 2023 | -103.76M |
| March 31, 2023 | -87.82M |
| December 31, 2022 | -78.77M |
| September 30, 2022 | -56.51M |
| June 30, 2022 | -45.43M |
| March 31, 2022 | -61.93M |
| December 31, 2021 | -60.09M |
| September 30, 2021 | 23.08M |
| June 30, 2021 | 15.39M |
| March 31, 2021 | 8.746M |
| December 31, 2020 | -5.836M |
| September 30, 2020 | -118.92M |
| June 30, 2020 | -122.76M |
| March 31, 2020 | -120.01M |
| December 31, 2019 | -109.24M |
| September 30, 2019 | -102.46M |
| June 30, 2019 | -97.34M |
| March 31, 2019 | -31.44M |
| December 31, 2018 | -22.37M |
| Date | Value |
|---|---|
| September 30, 2018 | -9.402M |
| June 30, 2018 | 1.239M |
| March 31, 2018 | -51.71M |
| December 31, 2017 | -54.88M |
| September 30, 2017 | -56.73M |
| June 30, 2017 | -60.24M |
| March 31, 2017 | -59.90M |
| December 31, 2016 | -48.10M |
| September 30, 2016 | -39.02M |
| June 30, 2016 | -33.44M |
| March 31, 2016 | -26.09M |
| December 31, 2015 | -21.50M |
| September 30, 2015 | -23.16M |
| June 30, 2015 | -19.86M |
| March 31, 2015 | -19.84M |
| December 31, 2014 | -17.68M |
| September 30, 2014 | -16.91M |
| June 30, 2014 | -15.85M |
| March 31, 2014 | 1.557M |
| December 31, 2013 | 2.829M |
Free Cash Flow Range, Past 5 Years
-122.76M
Minimum
Jun 2020
23.08M
Maximum
Sep 2021
-69.30M
Average
-87.82M
Median
Mar 2023
Free Cash Flow Benchmarks
| Nektar Therapeutics | -193.47M |
| Stereotaxis Inc | -9.505M |
| Cerus Corp | -47.76M |
| Avid Bioservices Inc | -38.50M |
| Rigel Pharmaceuticals Inc | -20.74M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -17.37M |
| Cash from Investing (Quarterly) | -30.20M |
| Cash from Financing (Quarterly) | 36.48M |
| Free Cash Flow Per Share (Quarterly) | -0.3565 |
| Free Cash Flow to Equity (Quarterly) | -19.42M |
| Free Cash Flow Yield | -226.6% |